Drug and Alcohol Dependence
Volume 58, Issue 1 , Pages 27-33 , 1 February 2000

Gender differences in hostility of opioid-dependent outpatients: role in early treatment termination

  • Nancy M Petry

      Affiliations

    • Corresponding Author InformationCorresponding author. Present address: Department of Psychiatry, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030-2103, USA. Tel.: +1-860-679-2177; fax: +1-860-679-4077
    • ,
  • Warren K Bickel

Received 1 April 1999 ,Accepted 19 May 1999.

References 

  1. Alterman AI, Cacciola JS. The antisocial personality disorder diagnosis in substance abusers: Problems and issues. J. Nerv. Ment. Dis. 1991;179:401–409
  2. Altman H, Evenson R, Cho DW. Prediction length of stay by patients hospitalized for alcoholism and drug dependence. J. Stud. Alcohol. 1978;39:197–201
  3. Anglin B, Hser Y, Booth MW. Sex differences in addict careers: 4. Treatment. Am. J. Drug Alcohol Abuse. 1987;13:253–280
  4. Baekland F, Lundwall L. Dropping out of treatment: A critical review. Psychol. Bull. 1975;82(5):738–783
  5. Ball SA. The validity of an alternative five factor measure of personality in cocaine abusers. Psychol. Assess. 1995;7:148–154
  6. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag; 1991;
  7. Ball SA, Schottenfeld R. A five-factor model of personality and addition, psychiatric and AIDS risk severity in pregnant and postpartum cocaine misusers. Subst. Use Misuse. 1997;32:25–41
  8. Ball JC, Rosen L, Flueck J, Nurco DN. The criminality of heroin addicts when addicted and when off opiates. In:  Inciardi JA editors. The drug–crime connection. 5:Beverly Hills: Sage Publications; 1981;p. 39–65
  9. Biaggio MD, Supplee K, Curtis N. Reliability and validity of four anger scales. J. Pers. Assess. 1981;45:639–647
  10. Bickel WK, Amass L. Buprenorphine treatment of opioid dependence: A review. Exp. Clin. Psychopharmacol. 1995;3:477–489
  11. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clin. Pharm. Ther. 1988;43:72–78
  12. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans. J. Pharm. Exp. Ther. 1988;247:47–53
  13. Bickel WK, Amass L, Higgins ST, Badger GJ, Esch RA. Effects of behavioral treatment during opioid detoxification with buprenorphine. J. Consult. Clin. Psychol. 1997;65:803–810
  14. Brown LS, Alterman AI, Rutherford MJ, Cacciola JS. Addiction Severity Index scores of four racial/ethnic and gender groups of methadone maintenance patients. J. Subst. Abuse. 1993;5(Suppl. 3):269–279
  15. Buss AH, Durkee A. An inventory for assessing different kinds of hostility. J. Consult. Psychol. 1957;21(Suppl. 4):343–349
  16. Carroll KM, Ball S, Rounsaville BJ. A comparison of alternate systems for diagnosing antisocial personality disorder in cocaine abusers. J. Nerv. Mental Dis. 1993;181(Suppl. 7):436–443
  17. el-Guebaly N. Substance use disorders and mental illness: The relevance of comorbidity. Can. J. Psychiatry. 1995;40(Suppl. 1):2–3
  18. Fals-Steward W, Lucente S. Effect of neurocognitive status and personality functioning on length of stay in residential substance abuse treatment: An integrative study. Psychol. Addict. Behav. 1994;8(Suppl. 3):179–190
  19. Fals-Steward W, Schafer J. The relationship between length of stay in drug-free therapeutic communities and neurocognitive functioning. J. Clin. Psychol. 1992;48(Suppl. 4):539–543
  20. Fishbein DH, Reuland M. Psychological correlates of frequency and type of drug use among jail inmates. Addict. Behav. 1994;19:583–598
  21. Gutierres SE, Todd M. The impact of childhood abuse on treatment outcomes of substance users. Profess. Psycho: Res. Pract. 1997;28(Suppl. 4):348–354
  22. Han K, Weed NC, Calhoun RF, Butcher JN. Psychometric characteristics of the MMPI-2 Cook–Medley Hostility Scale. J. Pers. Assess. 1995;65(Suppl. 3):567–585
  23. Hubbard RL, Marsden ME, Rachal JV. Drug abuse treatment: A national study of effectiveness. Chapel Hill, NC: University of North Carolina Press; 1989;
  24. Joe GW, Simpson DD. Retention in treatment of drug users: 1971–1972 DARP admissions. Am. J. Drug Alcohol Abuse. 1975;2:63–71
  25. Karuntzos GT, Caddell JM, Dennis ML. Gender differences in vocational needs and outcomes for methadone treatment clients. Theme Issue: Treatment of opioid dependence: Current issues and future prospects. J. Psychoact. Drugs. 1994;26(Suppl. 2):173–180
  26. Kosten TR, Rounsaville BJ, Kleber HD. DSM-III personality disorders in opiate addicts. Compr. Psychiatry. 1982;23:572–581
  27. Kranzler HR, Del Boca FK, Rounsaville BJ. Comorbid psychiatric diagnosis predicts three-year outcomes in alcoholics: A posttreatment natural history study. J. Stud. Alcohol. 1996;57:619–626
  28. Lawler KA, Harralson TL, Armstead CA, Schmied LA. Gender and cardiovascular responses: What is the role of hostility?. J. Psychosom. Res. 1993;37(Suppl. 6):603–613
  29. Leal J, Ziedonis D, Kosten T. Antisocial personality disorder as a prognostic factor for pharmacotherapy of cocaine dependence. Drug Alcohol Depend. 1994;35(Suppl. 1):31–35
  30. Levy SJ, Doyle KM. Attitudes toward women in a drug abuse treatment program. J. Drug Issues. 1974;4:428–434
  31. Ling W, Charuvastra VC, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts. Arch. Gen. Psychiatry. 1976;33:709–720
  32. Marsh JC, Miller NA. Female clients in substance abuse treatment. Int. J. Addict. 1985;20:995–1019
  33. McCormick R, Smith M. Aggression and hostility in substance abusers: The relationship to abuse patterns coping style and relapse triggers. Addict. Behav. 1995;20(Suppl. 5):555–562
  34. McLellan AT. Patient characteristics associated with outcome. In:  Cooper JR,  Altman F,  Brown BS, et al. editor. Research on the treatment of narcotic addiction: State of the Art, NIDA Treatment Research Monograph Series, No. ADM 83-1281, National Institute on Drug Abuse, Rockville, MD. 1983;p. 500–529
  35. McLellan AT, Luborsky L, O’Brien CP, Woody GE, Druley KA. Is treatment for substance abuse effective?. J. Am. Med. Assoc. 1982;247:1423–1427
  36. McLellan AT, Luborsky L, Cacciola J, Griffith JE. New data from the Addiction Severity Index. Reliability and validity in three centers. J. Nerv. Ment. Dis. 1985;173:412–423
  37. McLellan AT, Luborsky L, O’Brien CP, Barr HL. Alcohol and drug abuse treatment in three difference populations: Is there improvement and is it predictable?. Am. J. Drug Alcohol Abuse. 1986;12(1):101–120
  38. McMahon RC, Kelley A, Kouzekanani K. Personality and coping styles in the prediction of dropout from treatment for cocaine abuse. J. Pers. Assess. 1993;61(Suppl. 1):147–155
  39. Metzger DS, Woody GE, McLellan AT, O’Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. J. Acquir. Immune Defic. Syndr. 1993;6:1049–1056
  40. Moss HB. Psychopathy, aggression and family history in male veteran substance abuse patients: A factor analytic study. Addict. Behav. 1989;14(Suppl. 5):565–570
  41. Nurco DN, Shaffer JW, Ball JC, Kinlock TW. Trends in the commission of crime among narcotic addicts over successive periods of addiction and nonaddiction. Am. J. Drug Alcohol Abuse. 1984;10:481–489
  42. Petry NM, Bickel WK. Buprenorphine self-administration in buprenorphine-maintained outpatients: Effects of an alternate reinforcer, behavioral economic analysis of demand and dissociation of subjective and reinforcing effects. Exp. Clin. Psychopharm. 1999;7(Suppl. 1):1–11
  43. Petry NM, Bickel WK, Badger GJ. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clin. Pharmacol. Ther. 1999;66:306–314
  44. Petry, N.M., Bickel, W.K., Badger, G.J., 1999b. A comparison of four buprenorphine dosing regimens using open-dosing procedures. Is twice weekly dosing possible? In review.
  45. Project Match Research Group . Project MATCH secondary a priori hypotheses. Addiction. 1997;92:1671–1698
  46. Ravndal E, Vaglum P. Changes in antisocial, aggressiveness during treatment in hierarchical therapeutic community. Acta Psychiatr. Scand. 1991;84:524–530
  47. Reed BG. Developing women-sensitive drug dependence treatment services: Why so difficult?. J. Psychoact. Drugs. 1987;19:151–164
  48. Renson GJ, Adams JE, Tinklenberg JR. Buss–Durkee assessment and validation with violent versus non-violent chronic alcohol abusers. J. Consult. Clin. Psychol. 1978;46:360–361
  49. Rosen MI, Wallace EA, McMahon TJ, Pearall HR. Buprenorphine: Duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend. 1994;35(Suppl. 2):141–149
  50. Rounsaville BJ, Kosten TR, Weissman MM, Kleber HD. Prognostic significance of psychopathology in treated opiate addicts: A 2.5-year follow-up study. Arch. Gen. Psychiatry. 1986;43(Suppl. 8):739–745
  51. Rounsaville BJ, Kosten TR, Kleber HD. The antecedents and benefits of achieving abstinence in opioid addicts: A 2.5-year follow-up study. Am. J. Drug Alcohol Abuse. 1987;13(Suppl. 3):213–229
  52. Saxon AJ, Calsyn DA, Jackson TR. Longitudinal changes in injection behaviors in a cohort of injection drug users. Addiction. 1994;89(Suppl. 2):191–202
  53. Schuckit MA. The clinical implications of primary diagnostic groups among alcoholics. Arch. Gen. Psychiatry. 1985;42:1043–1049
  54. Simpson DD. The relation of time spent in drug abuse treatment to posttreatment outcomes. Am. J. Psychiatry. 1979;136:1449–1453
  55. Simpson DD. Treatment for drug abuse: Follow-up outcomes and length of time spent. Arch. Gen. Psychiatry. 1981;39(Suppl. 8):875–880
  56. Simpson DD, Sells SB. Effectiveness of treatment for drug abuse: An overview of the DARP research program. Adv. Alcohol Subst. Abuse. 1982;2(Suppl. 1):7–29
  57. Stark MJ. Dropping out of substance abuse treatment: A clinically oriented review. Clin. Psychol. Rev. 1992;12:93–116
  58. Stark MJ, Campbell BK. Personality, drug use and early attrition from substance abuse treatment. Am. J. Drug Alcohol Abuse. 1988;14(Suppl. 4):475–485
  59. Strain EC, Stitzer ML, Liebson IA, et al.  Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am. J. Psychiatry. 1994;151:1025–1030
  60. Vickers-Lahti M, Garfield F, McCusker J, Hindin R. The relationship between legal factors and attrition from a residential drug abuse treatment program. J. Psychoact. Drugs. 1995;27(Suppl. 1):17–25
  61. Woody GE, McLellan AT, Luborsky L, O’Brien CP, Blaine J, Fox S, et al. Severity of psychiatric symptoms as a predictor of benefits from psychotherapy: The Veterans Administration-Penn study. Am. J. Psychiatry. 1984;141:1172–1177
  62. Woody GE, McLellan AT, Luborsky L, O’Brien CP. Psychotherapy in community methadone programs: A validation study. Am. J. Psychiatry. 1995;152:1302–1308
  63. Woodhouse LD. An exploratory study of the use of life history methods to determine treatment needs for female substance abusers. Resp. Victim Women Child. 1990;13:12–15

PII: S0376-8716(99)00058-7

Drug and Alcohol Dependence
Volume 58, Issue 1 , Pages 27-33 , 1 February 2000

Article Tools

* Image Usage & Resolution